Down 9%: Is OncoMed a Bad News Buy?

OncoMed  shareholders had a rough day, with potential issues with mild-to-moderate bone-related adverse events causing a halt in a phase 1 trial for two of the company's drugs. The big question, of course, is whether this makes for an attractive investment situation. Could this be an opportunity to get shares of a company paired with the likes of Celgene  and other big pharmas on several drug candidates for cheap?

In the video below, health care analysts Michael Douglass and David Williamson lay out OncoMed's strengths, but also the weaknesses that will keep them away from the stock for the time being.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need to Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

The article Down 9%: Is OncoMed a Bad News Buy? originally appeared on

David Williamson has no position in any stocks mentioned. Michael Douglass owns shares of Celgene. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story